Acrivon Therapeutics Inc

Our Board consists of eight directors and is divided into three classes with staggered three-year terms:

Class I – Term expiring at the 2026 Annual Meeting of Stockholders

Michael Tomsicek, M.B.A.

Charles Baum, M.D., Ph.D.

Class II – Term expiring at the 2024 Annual Meeting of Stockholders

Kristina Masson, Ph.D., M.B.A.

Ivana Magovčević-Liebisch, Ph.D., J.D.

Class III – Term expiring at the 2025 Annual Meeting of Stockholders

Santhosh Palani, Ph.D., C.F.A.

At the Annual Meeting, each of Kristina Masson, Ph.D., M.B.A, Sharon Shacham, Ph.D., M.B.A. and Ivana Magovčević-Liebisch, Ph.D., J.D. will be standing for election as a Class II director, to hold a three-year term expiring at our 2027 Annual Meeting. The directors will hold office until her successor has been elected and qualified or until a director’s earlier resignation or removal.

The nominating and corporate governance committee has recommended, and the Board has approved, the nomination of Drs. Masson, Shacham and Magovčević-Liebisch to stand for election at the 2024 Annual Meeting. Dr. Magovčević-Liebisch is standing for election by our stockholders for the first time, and was originally identified as a candidate to join the Board by an independent third-party search firm. The nominees have consented to serve if elected. However, if a nominee fails to stand for election, declines to accept election, or is otherwise unavailable for election prior to our 2024 Annual Meeting, proxies solicited by our Board will be voted by the proxy holders for the election of any other person or persons as the Board may recommend, or our Board, at its option, may reduce the number of directors that constitute the entire Board.